Community Research and Development Information Service - CORDIS

  • European Commission
  • CORDIS
  • Projects and Results
  • Periodic Reporting for period 1 - INPACT (Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training , and communication.)
H2020

INPACT Report Summary

Project ID: 644167
Funded under: H2020-EU.1.3.3.

Periodic Reporting for period 1 - INPACT (Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training , and communication.)

Reporting period: 2015-02-01 to 2017-01-31

Summary of the context and overall objectives of the project

INPACT aims at the pre-clinical development of innovative drugs and drug formulations against selected cancers (eg prostate cancer) and pathogenic bacteria (eg S. aureus). The INPACT consortium allies the expertise of both academic and industrial R&D partners that contribute with their own unique technologies to achieve new drugs that are only possible to develop in an integrative effort. Academic partners have unique knowledge and technologies on supercharged viral proteins-derived cell-penetrating peptides (eg from Dengue virus) and ultra-resistant cyclic peptides that may be transferred to the industrial partners, which in turn have specialized proprietary technologies on anticancer and/or peptide drugs’ technologies. The judicious exchange of knowledge among partners will lead to new resistant peptides for trans-barrier delivery of drugs (eg cyclic peptide-drug chimeras) and bacterial killing (both planktonic and biofilms). INPACT includes four leading academic partners (from Portugal, Spain, Australia, and Brazil) and three consolidated biotech SMEs (one from Portugal and two Spain).
In addition to the R&D project itself, INPACT involves at the highest possible level a top business school in Europe (IESE, Barcelona, Spain), a consolidated media partner specialised in science communication (Ciencia Hoje, Rio de Janeiro, Brazil) and experts in international science funding from one of the top US universities (University of Stanford). The consortium will be the perfect environment for young researchers to acquire knowledge and skills in science, technology, entrepreneurship, business, and communication so they can pro-actively tailor their career path in a life-long learning perspective. This is a contribution towards the advancement of Europe through the use of research and education for societal development and economic growth.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The INPACT team has been very active in intersectoral and/or intercontinental activities, most of the participants being involved in secondments either has hosts or sender institutions. Scientific and outreaching activities have tangible outputs, as well as technology transfer. For instance, peptides able to translocate the Blood-brain barrier reversibly carrying biopharmaceutcals have been discovered and a patent has been filed to secure IP protection.
The figures of implemented fellow*months reflect the purpose of INPACT to train and increase the career prospects of young people and gender balance.
Two general meetings of the consortium have occurred, the kick-off meeting (in Barcelona, Spain) and the first annual meeting (Lisbon, Portugal, March 9th 2016).

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

New products were translated from Academia to Industrial partners for further development in the field of CNS-associated diseases, including cancer metastasis. A patent was filed.
The proof of concept of new products or technologies, such as anti-cancer and antimicrobial peptides, has been established. Eight scientific papers have been published.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top